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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not topical
corticosteroids prevent and/or reduce symptoms and severity of radiation dermatitis in breast
cancer patients receiving radiation therapy to the chest wall.
Study Design: Review of three double blind randomized controlled clinical trials (RCTs)
published in 2002, 2007, and 2011
Data Sources: Three peer-reviewed RCTs were found using PubMed. These studies compared
topical corticosteroid use against various placebos in the treatment of radiation dermatitis
Outcomes Measured: Severity of radiation dermatitis as reported using quality of life
questionnaires, Skindex scores, and Radiation Therapy Oncology Group (RTOG) scaling.
Significant outcomes were evaluated through the use of p-values and t-tests.
Results: Schmuth et al (2002) found significant difference between the two treatment arms for
embarrassment (p<0.05) and approached significance for dimensions of fear (p=0.06) and
physical discomfort (p=0.057). Furthermore, while all dimensions worsened in the dexpanthenol
treated group, only four of seven dimensions worsened in the corticosteroid group. In Miller et al
(2011) itching, irritation, the persistence of symptoms, the recurrence of toxicity symptoms, and
annoyance with dermatitis were all reduced by a statistically significant fraction in the treatment
group compared with the placebo group in the Skindex-16. The total Skindex-16 score, however,
did not reach statistical significance between the MMF arm and placebo arm with a p=0.07. In
Omidvari et al (2007) all patients developed some degree of radiation dermatitis. However,
patients receiving betamethasone had less severe acute radiation dermatitis than the petrolatum
receiving or control groups throughout the course of the study; this difference was only
significant by the end of the third week (p=0.027).
Conclusion: Conflicting results from these three RCTs demonstrates that the use of topical
corticosteroids in the prevention and treatment of radiation dermatitis is inconclusive
Key Words: Corticosteroids, Radiation Dermatitis, Breast Cancer, Chest wall Irradiation
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INTRODUCTION
With an increase in technology and screening, there is now better detection and treatment
for breast cancer. While there is great benefit in the improved management of breast cancer, it is
essential to consider the subsequent side effects of treatment and how best to manage those.
Radiation therapy, for example is used in definitive, preoperative, and postoperative or palliative
treatment in the management of breast cancer.1 Because of the increase in radiation therapy there
has also been an increase in cases of radiation dermatitis, an acute injury within hours to weeks
after radiation exposure as a result of structural tissue damage, generation of short-lived free
radicals, irreversible double stranded breaks in nuclear and mitochondrial DNA, and initiation of
an inflammatory response in the epidermis and dermis.2 The exact mechanism of radiation
induced inflammation is not fully understood, but research to date suggests that fibroblasts are a
key cell type responsible for the late or delayed effect of radiation.2
Care for this side effect is essential because without reduction in the cosmetic and
uncomfortable disturbance of radiation dermatitis from therapy, patients often become noncompliant with appropriate breast cancer treatment.1 Due to the variance in severity and response
to skin treatments, there are no specific guidelines on the number of visits each year for radiation
dermatitis. Regardless, with an increase in cases of radiation dermatitis (affecting about 87% of
patients receiving radiation1), it is very fortunate that mid-level practitioners, like physician
assistants, are capable of managing these effects of radiation.
In the treatment of any dermatitis, it is necessary to consider the treatment options to
reduce discomfort, cosmetic disturbances, and recurrence. Unfortunately, there is currently no
treatment of choice to benefit all patients with radiation dermatitis1,3, making it necessary for
practitioners to be aware of all pharmacologic as well as non-pharmacologic management
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strategies for managing the dermatitis. Though there are several different recommendations for
treatment, all studies imply the importance of maintaining appropriate hygiene and avoidance of
obvious irritants. The affected skin, for example, should remain clean and dry after washing with
lukewarm water, and mild, synthetic soaps. Patients must avoid skin irritants including sun
exposure, perfumes and alcohol based lotions, and instead use unscented, lanolin-free, water
based moisturizers. Loose fitting clothes will also benefit the patient in order to avoid friction
injuries to the affected skin.1,3,4,5
After considering the number of simple recommendations for their radiation dermatitis,
patients and practitioners must choose among the assortment of topicals used in the treatment of
this conditions. Aloe vera, calendula, petrolatum-based emollients, trolamine-containing
formulations, topical corticosteroids, and sucralfate cream are the most commonly suggested
topicals1; no general agreement, however, exists concerning how to treat or prevent radiation
dermatitis.3 Though there are a number of options to choose from, this selective EBM review
seeks to explore the potential benefits of using topical corticosteroids as the sole topical
treatment for radiation dermatitis. Topical corticosteroids, if beneficial in the prevention and
treatment of radiation induced dermatitis, are a good option as a topical treatment because they
are both affordable, ranging from $27 to $42 (in the reviewed studies)6,7,8, and have limited
additional side effects.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not topical
corticosteroids prevent and/or reduce symptoms and severity of radiation dermatitis in breast
cancer patients receiving RT to the chest wall.
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METHODS
Three double blind randomized controlled studies were used in this review. Each study
followed a group of women who had previously had surgical treatment for breast cancer and
were to undergo radiation therapy (RT). Over the course of their RT, topical corticosteroids were
introduced into the experimental groups. The specific topical corticosteroid, dose, and
application duration varied across the studies, as did the structure of each control group; the
commonality, however, was the absence of corticosteroid cream application for the comparison
control group. After the application of the creams to the irradiated skin for a specified duration,
patients were asked to be assessed for or report the outcome of their treatment based on the
severity of their radiation dermatitis.
Key words used in search included corticosteroids, radiation dermatitis, breast cancer,
and chest wall irradiation. The chosen articles were all written in English and published in peerreviewed journals between 2002 and 2011. Each was found through PubMed database, and
selected based on its relevance to my initial clinical question and its ability to be correlated to the
outcome in question. The inclusion criteria consisted of RCT’s and a population of female breast
cancer patients with previous surgical treatment and were receiving RT. Women receiving other
therapies for their radiation dermatitis were excluded, as were women with a history of other skin
conditions, or inflammatory breast carcinoma. In the analysis of each trial, p-values, t-tests,
and/or Kruskal-Wallis tests were utilized to determine the summary of statistical significance of
topical corticosteroid use.
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Table 1: Demographics & Characteristics of Included Studies
Study

Type #Pts Age
(yrs)
Omidvari RCT 58
20(2007)1
70

Schmuth
(2002)3

RCT 31

1880

Miller
(2011)4

RCT 176

>18

Inclusion
Criteria
Female pts who
underwent
modified radical
mastectomy and
chemo for stage II
or III and needed
RT. Without hx of
RT, DM or
systemic CTD
Women receiving
RT for breast
cancer after breast
conserving surgery

Invasive breast or
ductal carcinoma
in situ; continuous,
definitive, or
adjuvant external
beam RT to whole
breast as part of
breast conservation
therapy or to breast
wall as part of
postmastectomy
RT

Exclusion
Criteria
Patients who were
receiving concurrent
chemotherapy and
radiation or were on
systemic
corticosteroids

W/
D
7

No prior history of
2
radiation dermatitis
or RT to same area;
pts with skin
conditions a/w barrier
defect or those
receiving systemic
corticosteroids
Inflammatory
10
carcinoma, allergy to
mometasone,
imidazolidinyl urea,
or formadelhyde; use
of leukotriene
inhibitors or OTC
med with
hydrocortisone/
corticosteroid prep;
pregnant or breast
feeding; bilateral
breast carcinoma

Interventions
Betamethasone
0.1%

Methylprednis
olone 0.1%

Mometasone
fuoate 0.1%

OUTCOMES MEASURED
Each breast cancer patient who successfully adhered to all experimental procedures, was
asked to either complete a quality of life questionnaire/Skindex-score survey, or was evaluated
with RTOG scaling to determine the results of topical corticosteroid use during and after RT.
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These assessments successfully measured the impact of the RT on the skin in terms of severity,
patient symptoms, and morbidity associated with the skin changes.
Schmuth et al (2002) assessed patients’ quality of life (QOL) using a medical outcome
study 36-item short form health survey as well as the Skindex survey. The former was developed
to identify general physical and mental components of health related QOL with 36 items
measuring eight general health dimensions.3 The Skindex scoring system was slightly different,
as it was developed to identify skin disease specific health related QOL rather than that for
general health. This 61-item version included two physical (discomfort and limitations) and three
major psychosocial (cognitive, social, and emotional) dimensions as they related to QOL in
regards to skin disease.3 Scores for both assessments of QOL were standardized to 100, with the
higher scores indicating a better outcome.
In Miller et al’s study (2011), patient reported outcomes were measured using the
Skindex-16 and the skin toxicity assessment. The skin toxicity assessment tool is a skin-specific
instrument that consisted of a provider assessment as well as patient reported discomfort. The
patient completed QOL assessment consisted of six questions, with responses ranging from 0
(poor QOL) to 10 (best QOL).
Rather than assessing acute radiation dermatitis with QOL surveys like the previously
explained studies, Omidvari et al. utilized RTOG acute radiation morbidity scoring criteria for
the skin. With each visit throughout the study, patient’s irradiated skin was scored grades 0-4
based on the level of dermatitis experienced by the patient. Grade 0 referred to no skin changes
over baseline, or no radiation dermatitis. Grades 1-4 represented skin changes ranging from
erythema, dry desquamation, and decreased sweating to ulceration, hemorrhage, and necrosis. In
terms of patient outcome and perspective, grade 1 was considered less bothersome than the
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obvious pain experienced by patients with grade 4 radiation dermatitis.1 Thus, the higher the
grade assigned to the patient, the worse radiation dermatitis was to be experienced by the patient.
RESULTS
Three double blind RCT’s compared the severity of radiation dermatitis in female, breast
cancer patients receiving standardized RT after surgical treatment with topical corticosteroid
treatment as compared to other topical therapies for the skin condition. Miller et al (2011) used
patients receiving the non-steroidal topical cream as the control group while the other two studies
had a control group of individuals using no topical treatment. Omidvari et al (2007) and Schmuth
et al (2002), thus had three groups of individuals participating in the study; those receiving
topical corticosteroids, a non-steroidal cream, and a group without topical cream treatment. The
inclusion and exclusion criteria of all three studies were relatively similar, with small differences
primarily seen in exclusion criteria (Table 1).1,3,4 Women receiving concurrent chemotherapy and
radiation were excluded from the studies because there is an additive response between
combined chemo and RT, leading to an increase in severity of radiation dermatitis.9
Data from all trials were reported as continuous data and could not be converted into a
dichotomous format; therefore, calculations evaluating tolerability, adverse events, and treatment
effects could not be computed. Patients in the studies received written information and consented
to participate in each trial prior to randomization. Because the women were free to withdraw,
each study lost a few participants over the course of the treatment for reasons that were not
shared. The losses, however, were minimal, ranging from 0-2 patients from a given group.1,3,4
In Schmuth et al (2002), a preliminary cohort of 15 patients who did not receive topical
therapy served as a control group. After obtaining the baseline data from the initial control
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cohort, a subsequent cohort of patients was recruited and randomized to one of the two groups in
a double blind fashion; one group receiving 0.5% dexpanthenol and the other the interventional
treatment in question, 0.1% methylprednisolone. The study population was selected from
consecutive patients attending the Department of Radiation Therapy in Innsbruck. Twenty three
patients were randomized into one of the two groups applying a specific type of cream. Two
patients withdrew from the methylprednisolone group due to either inadequate adherence to
treatment (n=1) or patients’ request (n=1). At the completion of the study, there were 11 patients
using the topical dexpanthenol and 10 patients using the methylprednisolone. The severity of
each patients’ radiation dermatitis was monitored weekly throughout the study; with six weeks of
fractionated RT and two weeks of follow-up after its completion.3
Clinical and functional parameters with questionnaire based QOL assessment of patient’s
own experience of their disease and response to therapy was performed using the SF-36 and
Skindex QOL assessments. Of the 21 patients who completed the study, only 16 and 17 patients
for the Skindex and SF-36 questionnaires, respectively, were usable, yielding final response rates
of 76% and 81%, respectively. An unpaired t-test was first used to calculate differences in QOL
scores between the treatment arms. Post-treatment QOL scores were then compared with the
pretreatment baseline scores by the paired t-test; a p value of <0.05 was considered significant.
In both the SF-36 and Skindex inventories, scores largely deteriorated from pretreatment to post
treatment, reflecting appearance of radiation dermatitis in all subjects. Severity of change,
however, differed between those treated with corticosteroids versus dexpanthenol. While all
dimensions worsened in the dexpanthenol treated group, only four of seven dimensions
worsened in the corticosteroid group, indicating that topical corticosteroids may in part reverse
negative impact of radiation dermatitis. The difference between the two treatment groups was
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significant for the dimension of embarrassment and approached significance for the dimensions
of fear and physical discomfort.3
Table 2: Difference in post-treatment v. pretreatment QOL scores for 0.1%
Methylprednisolone v. 0.5% Dexpanthenol
Embarrassment
Fear
Physical discomfort

P values
<0.05 (value not given)
0.06
0.057

Miller et al (2011) recruited 176 patients between September and December 2007, with a
follow up period of two weeks after RT completion. Of the 176 patients 90 were randomly
assigned to the treatment group applying 0.1% mometasone fuorate and 86 were randomly
assigned to the control group with the application of a placebo cream. After randomization, 5
patients in the MMF arm and 2 patients in the placebo arm declined participation, for 169
eligible patients. Data was missing for 3 patients, leaving 166 patients eligible for evaluation.
The secondary endpoints of patient reported skin toxicity (outcome measures using Skindex-16
and skin toxicity assessment tool) and QOL were analyzed by comparing the mean responses
between the study arms using the Kruskal-Wallis test. Itching, irritation, the persistence of
symptoms, the recurrence of toxicity symptoms, and annoyance with dermatitis were all reduced
by a statistically significant fraction in the treatment group compared with the placebo group in
the Skindex-16. The total Skindex-16 score, however, did not reach statistical significance
between the MMF arm and placebo arm with a p=0.07. The patients in the MMF arm also
reported less discomfort and burning, less itching, and less redness using the Skin Toxicity
Assessment tool and symptom experience diary.4
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Table 3: Patient-reported maximum Skindex-16, Skin Toxicity Assessment Tool, and
Symptom Experience Diary toxicity scores
Maximum Skindex-16 score
MMF (n=83)
Placebo (n=83)
2.3
3.1
2.6
3.4
2.3
3.0
1.2
1.8
1.4
1.7
Skin Toxicity Assessment score
Discomfort or burning
1.5
2.1
Itching
1.5
2.2
Symptom Experience Diary score
Redness
5.1
6.8
*Lower score indicated less toxicity
Toxicity Characteristic
Itching
Irritation
Persistence/recurrence of sx
Annoyance of sx
Total Skindex-16 score

p value
0.008
0.01
0.02
0.04
0.07
0.02
0.002
0.003

In Omidvari et al (2007), eligible patients were female patients who previously
underwent modified radical mastectomy for pathologically proved breast cancer and needed
treatment with RT. During a three month period, 58 eligible patients were randomly assigned by
a computer based system to receive petrolatum, bethamethasone 0.1%, or none. Of the 58, seven
patients failed to complete the study course or were excluded because of declining to participate,
new onset DM (part of exclusion criteria), or prolonged radiation course due to other causes,
leaving 51 statistically evaluable cases at the end of the study. Of these 19 were in the
betamethasone group, 17 in the petrolatum group, and 15 in the control arm.1
The severity of the patients’ radiation dermatitis was determined using RTOG acute
radiation morbidity scoring criteria for skin as described earlier in the review. The
betamethasone acute radiation dermatitis (ARD) scoring was lower throughout the study. The
data showed that though patients applying topical corticosteroid did have ARD after RT, the
severity of the condition was lower and with a delayed onset when compared to the other two
arms of the study. Significant difference, however, was only found at the end of the third week,
only 26.3% of the betamethasone group with Grade I dermatitis compared with 64.7% and
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66.7% in the emollient and control arms respectively; these results were considered statistically
significant with a p-value of 0.027 (statistical significance achieved when p<0.05). Furthermore
with this data, the numbers needed to treat can be calculated with an NNT=2 patients. At the
conclusion of the topical treatment, all petrolatum-receiving patients developed Grade II or
higher ARD. At the same time, all patients had some degree of ARD but betamethasone
receiving patients had lower mean dermatitis grade than the other two arms. These results,
however did not reach significance but approached it with p=0.055.1
DISCUSSION
Using three double blind RCT’s this systematic review assessed the effects of topical
corticosteroids in the prevention and treatment of radiation dermatitis. Each article selected
female breast cancer patients who were undergoing radiation therapy post-surgical treatment for
their cancer and assessed the severity of radiation dermatitis that resulted from radiation to the
skin. The validity and blinding of each RCT was without error, however the sample sizes were
relatively small despite the low drop-out rate. Furthermore, quality of life was the main
assessment of patient outcomes in this study, but many others do exist.
Since their introduction to dermatologic therapy in 1952, topical corticosteroids have
become widely available and are very useful in treating numerous skin conditions. When use as
directed, this topical therapy is safe and very effective. Inappropriate or overuse, however, can
lead to several topical and systemic side effects that practitioners must be mindful of when
prescribing the topical medication. All topical corticosteroids, for example, have been shown to
cause some degree of skin atrophy. Topical corticosteroids are contraindicated as primary
treatment of bacterial infections because they are known to mask an infection by their
vasoconstrictive and anti-inflammatory properties, making diagnosis of infections more difficult.
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Other relative contraindications include Candidal, dermatophyte, and herpetic infections.10 Thus,
despite their broad availability, efficacy, relative low cost, ease of application, and lack of black
of box warnings, practitioners must be mindful of the risks associated with topical
corticosteroids.
CONCLUSION
The use of topical corticosteroids has shown inconclusive results in the prevention and
treatment of radiation dermatitis in breast cancer patients undergoing radiation therapy to the
chest wall. Though the data is statistically inconclusive, these studies support the notion that
topical corticosteroids do in fact provide some relief to patients experiencing radiation
dermatitis. Both Miller et al (2011) and Schmuth et al (2002) provided evidence a decrease in the
decline of QOL with the use of topical corticosteroids as compared to the control. Likewise,
Omidvari et al’s (2007) results demonstrated a delay in radiation dermatitis and an overall lower
grade radiation dermatitis score for those using the betamethasone in comparison to the group.
The use of topical corticosteroids in all studies relied on patient compliance and honest
report of application. Furthermore, the correct amount of the cream may not have been equal for
all patients throughout the study, possibly altering the true benefits/harms of using the steroid
creams. In the future, reliability could be improved by clinician administration of the cream in
order to standardize and control the proper use of the topical treatment. The known antiinflammatory effect of corticosteroids on the irradiated skin warrants further investigation.
Continuing research should continue to compare different treatments for the skin condition to
come to a consensus on how best to treat radiation dermatitis. Research should also consider the
duration of experiencing radiation dermatitis after completing radiation therapy.
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